Related Experiment Videos
Ventriculography with metrizamide
1Neurosurgical Department, Clinique St Pierre, Ottignies, Belgium.
Acta Radiologica. Supplementum
|January 1, 1977
Abstract:
Ventriculography with metrizamide (Amipaque) was performed in 150 patients. Side effects were mild and no severe reactions were observed. The low toxicity and the low epileptogenic activity of this contrast medium make positive contrast ventriculography a safe neuroradiologic procedure.
Insights
Metrizamide (Amipaque) is a safe contrast medium for ventriculography, a neuroradiologic procedure. Studies show it has low toxicity and minimal side effects in patients.
Area of Science:
- Neuroradiology
- Medical Imaging
- Contrast Media
Background:
- Ventriculography is a diagnostic imaging technique.
- Evaluating the safety and efficacy of contrast agents is crucial.
Purpose of the Study:
- To assess the safety and side effects of metrizamide (Amipaque) in ventriculography.
- To determine the suitability of metrizamide as a contrast medium for neuroradiologic procedures.
Main Methods:
- Ventriculography was performed on 150 patients.
- Metrizamide (Amipaque) was used as the positive contrast agent.
Main Results:
- Observed side effects were mild.
- No severe adverse reactions were reported in the patient cohort.
- Metrizamide demonstrated low toxicity and low epileptogenic activity.
Conclusions:
- Positive contrast ventriculography using metrizamide (Amipaque) is a safe neuroradiologic procedure.
- The low toxicity profile supports its use in clinical practice.